ClinicalTrials.gg
CompletedNCT00887263Updated Jan 21, 2016

Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)

A Phase 3 interventional study of Budesonide and Placebo in Oral Chronic Graft vs Host Disease, sponsored by Dr. Falk Pharma GmbH. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-01-21.

Sponsored by Dr. Falk Pharma GmbH · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 53 studies in Graft vs Host Disease with a site in Germany — 3 open to participants now, 9 under way, 4 of them phase 3. Graft vs Host Disease · Germany.

Enrollment
14th of 44
186 · median 69
Started
2009
with 2 others
Phase 3
17 of 53
1 open now
Registered
11th of 53
by date

Among the 53 studies in Graft vs Host Disease with a site in Germany, this one is the 14th largest by enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2009, is one of 17 in phase 3, and was the 11th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 148 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

3 of the 53 studies in Graft vs Host Disease with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 102 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 41 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Graft vs Host Disease with a site in Germany, or all of them as a file.
02

Study summary

The purpose of the study is to compare the efficacy and tolerability of budesonide 3 mg effervescent tablet (9 mg/day) compared to placebo for the treatment of patients with resistant oral cGvHD.

03

Conditions studied

  • Oral Chronic Graft vs Host Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >= 70
  • Oral chronic GvHD after haematopoietic stem cell transplantation
  • Oral cGvHD of erosive and/or ulcerative type
  • NIH scale >= 3
  • Resistant oral cGvHD with no oral response to conventional primary treatment

Exclusion criteria

Exclusion Criteria:

  • Uncertain diagnosis of resistant oral cGvHD
  • Symptomatic oral cGvHD of hyperkeratotic type solely
  • Current active oral bacterial, viral, or fungal infection
  • Unwilling to forego concurrent treatment for mucosal lesions and/or related oral pain
  • Requiring addition of new systemic therapy including , or radiation therapy
  • Local intestinal infection
  • Abnormal hepatic function or liver cirrhosis
  • If careful medical monitoring is not ensured: tuberculosis, cardiovascular disease, diabetes mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract, infection
  • treatment of oral cGvHD with topical steroids
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
186 participants (actual)

Study arms

  • Experimental
    A

    Drug: Budesonide

  • Placebo comparator
    B

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of patients with objective response

    Time frame: 12 weeks

Secondary outcomes

  1. Rate of complete/partial response, stable disease, progressive disease

    Time frame: 12 weeks

  2. Time to initial objective response

    Time frame: x weeks

  3. Rate of subjective improvement

    Time frame: 12 weeks

07

Study locations

2 sites
  • University of Regensburg
    Regensburg, 93053, Germany
  • The Hebrew University-Hadassah School of Dental Medicine, Department of Oral Medicine
    Jerusalem, 91120, Israel
08

References and documents

Publications

  • Elad S, Or R, Garfunkel AA, Shapira MY. Budesonide: a novel treatment for oral chronic graft versus host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Mar;95(3):308-11. doi: 10.1067/moe.2003.23. PubMed 12627101 ↗
  • Elad S, Zeevi I, Finke J, Koldehoff M, Schwerdtfeger R, Wolff D, Mohrbacher R, Levitt M, Greinwald R, Shapira MY. Improvement in oral chronic graft-versus-host disease with the administration of effervescent tablets of topical budesonide-an open, randomized, multicenter study. Biol Blood Marrow Transplant. 2012 Jan;18(1):134-40. doi: 10.1016/j.bbmt.2011.06.001. Epub 2011 Jun 12. PubMed 21703973 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2009
First posted
Apr 23, 2009
Start
Mar 2009
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Last update
Jan 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00887263
Responsible party
Sponsor
First posted
Apr 23, 2009
Start date
Mar 2009
Primary completion
Oct 2015
Completion
Oct 2015
Last update
Jan 21, 2016

Study contacts

Sharon Elad, DMD
principal investigator · University of Rochester Medical Center, Division of Oral Medicine, Eastman Institute for Oral Health

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion